Kyverna Therapeutics, Inc.
NASDAQ: KYTX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Warner Biddle
- Employees
- 130
- Headquarters
- Emeryville, United States
- IPO year
- 2024
- Market cap
- $377.5M
- Website
- https://kyvernatx.com
Loading KYTX…
Loading profile data…Frequently asked questions about KYTX
What does Kyverna Therapeutics, Inc. (KYTX) do?
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosi...
Where does KYTX trade?
Kyverna Therapeutics, Inc. (KYTX) trades on the NASDAQ.
What sector is KYTX in?
Kyverna Therapeutics, Inc. (KYTX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Kyverna Therapeutics, Inc.?
Warner Biddle is the chief executive officer of Kyverna Therapeutics, Inc. (KYTX).
Where is Kyverna Therapeutics, Inc. headquartered?
Kyverna Therapeutics, Inc. is headquartered in United States.
Does KYTX pay a dividend?
Kyverna Therapeutics, Inc. (KYTX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did KYTX go public?
Kyverna Therapeutics, Inc. (KYTX) completed its initial public offering in 2024.